The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
2.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
C07D 263/30 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to novel c-Myc mRNA translation modulators, composition and methods of preparation CA thereof, and uses thereof in the treatment of cancer.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
6.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software for use in the field of pharmaceuticals
and molecular biology; computer software for use in the
research and development of pharmaceutical preparations;
computer software for use in the pharmaceutical drug
development and discovery; computer software for the
analysis of biological or chemical activity; computer
software for the analysis of pharmaceutical properties of
molecules; computer software for the identification and
analysis of biological targets, networks and pathways; data
processing software; computer software for creating
searchable databases of information and data; computer
software for data analysis, pattern discovery, contextual
prediction, predictive analytics and predictive modelling;
computer software for compiling and analyzing scientific,
pharmaceutical and medical data; computer software for use
in accessing and importing data and information; interactive
databases; computer software for big data analytics. Pharmaceutical, scientific and medical research and
development; scientific and technological services and
research relating to the field of pharmaceuticals and
molecular biology; research and development of
pharmaceutical preparations and medicines; pharmaceutical
drug development and discovery services; providing online
non-downloadable software for use in the field of
pharmaceuticals and molecular biology; providing online
non-downloadable software for data analysis, pattern
discovery, contextual prediction, predictive analytics and
predictive modelling; providing online non-downloadable
software for the analysis of pharmaceutical properties of
molecules; providing online non-downloadable software for
the identification and analysis of biological targets,
networks and pathways; providing data processing software;
providing online non-downloadable software for creating
searchable databases of information and data; platform as a
service [PaaS], namely, software platforms for use in the
field of pharmaceuticals and molecular biology; software as
a service [SaaS], namely, software for use in the field of
pharmaceuticals and molecular biology; data mining;
providing online non-downloadable software for use in
accessing, importing, compiling and analyzing scientific,
pharmaceutical and medical data and information; providing
online non-downloadable software for big data analytics;
research and development of new products; cloud computing;
providing medical and scientific research information,
advisory and consultancy services in the field of
pharmaceuticals and molecular biology; providing
information, advisory and consultancy services regarding
research and development of pharmaceutical preparations and
medicines.
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software for use in the field of pharmaceuticals
and molecular biology; computer software for use in the
research and development of pharmaceutical preparations;
computer software for use in the pharmaceutical drug
development and discovery; computer software for the
analysis of biological or chemical activity; computer
software for the analysis of pharmaceutical properties of
molecules; computer software for the identification and
analysis of biological targets, networks and pathways; data
processing software; computer software for creating
searchable databases of information and data; computer
software for data analysis, pattern discovery, contextual
prediction, predictive analytics and predictive modelling;
computer software for compiling and analyzing scientific,
pharmaceutical and medical data; computer software for use
in accessing and importing data and information; interactive
databases; computer software for big data analytics. Pharmaceutical, scientific and medical research and
development; scientific and technological services and
research relating to the field of pharmaceuticals and
molecular biology; research and development of
pharmaceutical preparations and medicines; pharmaceutical
drug development and discovery services; providing online
non-downloadable software for use in the field of
pharmaceuticals and molecular biology; providing online
non-downloadable software for data analysis, pattern
discovery, contextual prediction, predictive analytics and
predictive modelling; providing online non-downloadable
software for the analysis of pharmaceutical properties of
molecules; providing online non-downloadable software for
the identification and analysis of biological targets,
networks and pathways; providing data processing software;
providing online non-downloadable software for creating
searchable databases of information and data; platform as a
service [PaaS], namely, software platforms for use in the
field of pharmaceuticals and molecular biology; software as
a service [SaaS], namely, software for use in the field of
pharmaceuticals and molecular biology; data mining;
providing online non-downloadable software for use in
accessing, importing, compiling and analyzing scientific,
pharmaceutical and medical data and information; providing
online non-downloadable software for big data analytics;
research and development of new products; cloud computing;
providing medical and scientific research information,
advisory and consultancy services in the field of
pharmaceuticals and molecular biology; providing
information, advisory and consultancy services regarding
research and development of pharmaceutical preparations and
medicines.
10.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-Myc mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
downloadable computer software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; downloadable computer software for use in the research and development of pharmaceutical preparations; downloadable computer software for use in the pharmaceutical drug development and discovery; downloadable computer software for the analysis of biological or chemical activity; downloadable computer software for the analysis of pharmaceutical properties of molecules; downloadable computer software for the identification and analysis of biological targets, networks and pathways; downloadable data processing software; downloadable computer software for creating searchable databases of information and data; downloadable computer software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; downloadable computer software for compiling and analyzing scientific, pharmaceutical and medical data; downloadable computer software for use in accessing and importing data and information; downloadable interactive databases in the fields of science, medicine and pharmaceuticals; downloadable computer software for big data analytics Pharmaceutical, and scientific research and development; medical research and development in the field of disease mechanisms, therapeutics and pharmaceuticals; scientific research and technological research services in the field of pharmaceuticals and molecular biology; research and development of pharmaceutical preparations and medicines; pharmaceutical drug development and discovery services; providing online non-downloadable software data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; providing online non-downloadable software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; providing online non-downloadable software for the analysis of pharmaceutical properties of molecules; providing online non-downloadable software for the identification and analysis of biological targets, networks and pathways; providing online non-downloadable data processing software; providing online non-downloadable software for creating searchable databases of information and data; platform as a service (PAAS) featuring computer software platforms for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; software as a service (SAAS) services featuring software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; data mining; providing online non-downloadable software for use in accessing, importing, compiling and analyzing scientific, pharmaceutical and medical data and information; providing online non-downloadable software for big data analytics; research and development of new products; cloud computing featuring software for data compiling, accessing, importing, searching, tracking, exploration, processing, integration, and analysis in the fields of science, medicine and pharmaceuticals; providing medical and scientific research information, advisory and consultancy services in the field of pharmaceuticals and molecular biology; providing information, advisory and consultancy services regarding research and development of pharmaceutical preparations and medicines
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable Computer software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; downloadable computer software for use in the research and development of pharmaceutical preparations; downloadable computer software for use in the pharmaceutical drug development and discovery; downloadable computer software for the analysis of biological or chemical activity; downloadable computer software for the analysis of pharmaceutical properties of molecules; downloadable computer software for the identification and analysis of biological targets, networks and pathways; downloadable data processing software; downloadable computer software for creating searchable databases of information and data; downloadable computer software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; downloadable computer software for compiling and analyzing scientific, pharmaceutical and medical data; downloadable computer software for use in accessing and importing data and information; downloadable interactive databases in the fields of science, medicine and pharmaceuticals; downloadable computer software for big data analytics Pharmaceutical, and scientific research and development; medical research and development in the field of disease mechanisms, therapeutics and pharmaceuticals; scientific research and technological research services in the field of pharmaceuticals and molecular biology; research and development of pharmaceutical preparations and medicines; pharmaceutical drug development and discovery services; providing online non-downloadable software data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; providing online non-downloadable software for data analysis, pattern discovery, contextual prediction, predictive analytics and predictive modelling; providing online non-downloadable software for the analysis of pharmaceutical properties of molecules; providing online non-downloadable software for the identification and analysis of biological targets, networks and pathways; providing online non-downloadable data processing software; providing online non-downloadable software for creating searchable databases of information and data; platform as a service (PAAS) featuring computer software platforms for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; software as a service (SAAS) services featuring software for data searching, tracking, exploration, processing, integration and analysis for use in the field of pharmaceuticals and molecular biology; data mining; providing online non-downloadable software for use in accessing, importing, compiling and analyzing scientific, pharmaceutical and medical data and information; providing online non-downloadable software for big data analytics; research and development of new products; cloud computing featuring software for data compiling, accessing, importing, searching, tracking, exploration, processing, integration, and analysis in the fields of science, medicine and pharmaceuticals; providing medical and scientific research information, advisory and consultancy services in the field of pharmaceuticals and molecular biology; providing information, advisory and consultancy services regarding research and development of pharmaceutical preparations and medicines
14.
COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
The present invention relates to novel Collagen I translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecule therapeutic
preparations for the regulation of mRNA translation and mRNA
biology, used in the treatment of fibrosis, cancers,
neurological diseases, infectious diseases, genetic
diseases, and other diseases. Research, analysis, and development of pharmaceuticals,
namely, small molecule therapeutic preparations for the
regulation of mRNA translation and mRNA biology, used in the
treatment of fibrosis, cancers, neurological diseases,
infectious diseases, genetic diseases, and other diseases.
18.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases Research, analysis, and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases. (1) Research, analysis, and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases.
21.
COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
C07D 263/30 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecules therapeutic
preparations for the regulation of mRNA translation and mRNA
biology, used in the treatment of fibrosis, cancers,
neurological diseases, infectious diseases, genetic
diseases, and other diseases; pharmaceutical and medical
preparations and substances for the treatment of fibrosis,
cancers, neurological diseases, infectious diseases, genetic
diseases, and other diseases; medical and pharmaceutical
chemical preparations for the treatment of fibrosis,
cancers, neurological diseases, infectious diseases, genetic
diseases, and other diseases; pharmaceutical preparations
for RNA targeted therapeutics; therapeutic agents for acting
on protein targets that regulate translational control of
gene expression. Research and development of pharmaceuticals, namely, small
molecule therapeutic preparations for the regulation of mRNA
translation and mRNA biology, used in the treatment of
fibrosis, cancers, neurological diseases, infectious
diseases, genetic diseases, and other diseases; research and
development of pharmaceutical preparations; pharmaceutical
drug development services; providing scientific research
information in the field of pharmaceuticals and molecular
biology; research, analysis, and development in the field of
pharmaceutical; research and development in the field of
bio-therapeutics for the treatment of fibrosis, cancers,
neurological diseases, infectious diseases, genetic
diseases, and other diseases; scientific investigations for
medical purposes; pharmaceutical, medical and scientific
research, and development; drug development and discovery;
scientific and technological services and research relating
to the field of pharmaceuticals.
23.
COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 471/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains three hetero rings
C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
C07D 491/02 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains two hetero rings
C07D 498/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 11/00 - Drugs for disorders of the respiratory system
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecules therapeutic
preparations for the regulation of mRNA translation and mRNA
biology, used in the treatment of fibrosis, cancers,
neurological diseases, infectious diseases, genetic
diseases, and other diseases; pharmaceutical and medical
preparations and substances for the treatment of fibrosis,
cancers, neurological diseases, infectious diseases, genetic
diseases, and other diseases; medical and pharmaceutical
chemical preparations for the treatment of fibrosis,
cancers, neurological diseases, infectious diseases, genetic
diseases, and other diseases; pharmaceutical preparations
for RNA targeted therapeutics; therapeutic agents for acting
on protein targets that regulate translational control of
gene expression. Research and development of pharmaceuticals, namely, small
molecule therapeutic preparations for the regulation of mRNA
translation and mRNA biology, used in the treatment of
fibrosis, cancers, neurological diseases, infectious
diseases, genetic diseases, and other diseases; research and
development of pharmaceutical preparations; pharmaceutical
drug development services; providing scientific research
information in the field of pharmaceuticals and molecular
biology; research, analysis, and development in the field of
pharmaceutical; research and development in the field of
bio-therapeutics for the treatment of fibrosis, cancers,
neurological diseases, infectious diseases, genetic
diseases, and other diseases; scientific investigations for
medical purposes; pharmaceutical, medical and scientific
research, and development; drug development and discovery;
scientific and technological services and research relating
to the field of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical and medical preparations and substances for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; medical and pharmaceutical chemical preparations for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical preparations for RNA targeted therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; therapeutic agents for acting on protein targets that regulate translational control of gene expression for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases. (1) Research and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; research and development of pharmaceutical preparations; pharmaceutical drug development services; providing scientific research information in the field of pharmaceuticals and molecular biology; research, analysis, and development in the field of pharmaceutical; research and development in the field of bio-therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; scientific investigations for medical purposes; pharmaceutical research and development, medical research, and scientific research and development, namely research and development of testing methods, treatments, and products; pharmaceutical, medical and scientific drug development and discovery; scientific and technological services and research relating to the field of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; pharmaceutical and medical preparations and substances for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; medical and pharmaceutical chemical preparations for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; pharmaceutical preparations for RNA targeted therapeutics; therapeutic agents for acting on protein targets that regulate translational control of gene expression Research and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; research and development of pharmaceutical preparations; pharmaceutical drug development services; providing scientific research information in the field of pharmaceuticals and molecular biology; research, analysis, and development in the field of pharmaceutical; research and development in the field of bio-therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; scientific investigations for medical purposes; pharmaceutical, medical and scientific research, and development; drug development and discovery; scientific and technological services and research relating to the field of pharmaceuticals
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical and medical preparations and substances for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; medical and pharmaceutical chemical preparations for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical preparations for RNA targeted therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; therapeutic agents for acting on protein targets that regulate translational control of gene expression for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases. (1) Research and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; research and development of pharmaceutical preparations; pharmaceutical drug development services; providing scientific research information in the field of pharmaceuticals and molecular biology; research, analysis, and development in the field of pharmaceutical; research and development in the field of bio-therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; scientific investigations for medical purposes; pharmaceutical research and development, medical research, and scientific research and development, namely research and development of testing methods, treatments, and products; pharmaceutical, medical and scientific drug development and discovery; scientific and technological services and research relating to the field of pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; pharmaceutical and medical preparations and substances for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; medical and pharmaceutical chemical preparations for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; pharmaceutical preparations for RNA targeted therapeutics; therapeutic agents for acting on protein targets that regulate translational control of gene expression Research and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; research and development of pharmaceutical preparations; pharmaceutical drug development services; providing scientific research information in the field of pharmaceuticals and molecular biology; research, analysis, and development in the field of pharmaceutical; research and development in the field of bio-therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; scientific investigations for medical purposes; pharmaceutical, medical and scientific research, and development; drug development and discovery; scientific and technological services and research relating to the field of pharmaceuticals
29.
COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The Trustees of the University of Pennsylvania (USA)
Anima Biotech Inc. (USA)
Inventor
Cooperman, Barry S.
Smilansky, Zeev
Goldman, Yale E.
Pan, Dongli
Abstract
Provided are methods for labeling transfer RNA comprising replacing the uracil component of a dihydrouridine of said transfer RNA with a fluorophore. The disclosed methods may comprise fluorescent labeling of natural tRNAs (i.e., tRNAs that have been synthesized in a cell, for example, in a bacterium, a yeast cell, or a vertebrate cell) at dihydrouridine (D) positions, or fluorescent labeling of synthetic tRNAs. In another aspect, the present invention provides methods for assessing protein synthesis in a translation system comprise providing a tRNA having a fluorophore substitution for the uracil component of a dihydrouridine in a D loop of the tRNA; introducing the labeled tRNA into the translation system; irradiating the translation system with electromagnetic radiation, thereby generating a fluorescence signal from the fluorophore; detecting the fluorescence signal; and, correlating the fluorescence signal to one or more characteristics of the protein synthesis in the translation system. The disclosed methods are useful in single molecule as well as in ensemble settings.
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
C07D 471/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains three hetero rings
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
C07D 491/02 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains two hetero rings
C07D 498/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 277/46 - Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
36.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
37.
C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
